Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia

Phase

Condition

Carcinoma

Dysfunctional Uterine Bleeding

Endometriosis

Treatment

Medroxyprogesterone acetate + Atorvastatin

Clinical Study ID

NCT05675787

2022PHB416

Ages 17-45
Female

Study Summary

To explore the treatment efficacy of medroxyprogesterone acetate plus atorvastatin in patients with atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EEC) for conservative treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Have a confirmed pathological diagnosis based upon hysteroscopy: histologicallyprove AEH or well-differentiated EEC G1 without myometrial invasion: 1. Untreatedpatients; 2. Patients with persistent lesions after one course (12 weeks) ofprogesterone therapy; 3. Patients who did not achieve complete remission after 2courses (24 weeks) of progesterone therapy;
No signs of suspicious extrauterine involvement on enhanced magnetic resonanceimaging (MRI) or enhanced computed tomography (CT) or ultrasound
Have a desire for remaining reproductive function or uterus
Good compliance with adjunctive treatment and follow-up

Exclusion

Exclusion Criteria:

Hypersensitivity or contradiction for using MPA or atorvastatin
Pregnancy or potential pregnancy
Confirmed diagnosis of any cancer in reproductive system
Already diagnosed with hyperlipidemia and using lipid-lowering drugs
Acute liver disease or liver tumor (benign or malignant) or renal dysfunction
Acute severe disease such as stroke or heart infarction or a history of thrombosisdisease
With other factors of reproductive dysfunction;
Strong request for uterine removal or other conservative treatment
Smoker (>15 cigarettes a day)
Drinker (>20 grams a day)

Study Design

Medroxyprogesterone acetate + Atorvastatin

January 06, 2023

October 31, 2025

Study Description

After diagnosed of AEH or EEC by hysteroscopy, patients meet the study criteria will be enrolled. The lipid content (lipid droplet, cholesterol and triglyceride) in endometrial lesion tissue was detected by Raman scattering instrument. And Age, height, weight, waistline, blood pressure, basic history of infertility and family cancer will be collected. Blood tests, including fasting blood glucose (FBG), fasting insulin (FINS), blood lipids, sex hormone levels, anti-müllerian hormone (AMH) and renal/liver function tests will be performed before treatment to evacuate their basic conditions. Each subject will receive body fat testing by Inbody 770.

Patients will receive MPA (Medroxyprogesterone acetate) 250-500 mg by mouth daily plus atorvastatin 20mg by mouth daily for at least 3 months. Then hysteroscopy will be used to evaluate the endometrial condition every 3 months, and intra-operative findings will be recorded. Complete response (CR) is defined as the reversion of endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response (PR) is defined as regression to hyperplasia with or without atypic; stable disease (SD) is defined as the persistence of the disease; and progressive disease (PD) is defined as the appearance of higher pathological progression, or myometrial invasion, or extra-uterine metastasis. Continuous therapies will be needed in PR. Patients with PD will be recommended for hysterectomy.

For patients remained SD after 9 months of treatment but refused hysterectomy, a multiple disciplinary discussion would be held for individual case, and alternative treatment would be given. Three months of maintenance treatment will be recommended for patients with CR, and participants will be followed up for at least 1 year.

Connect with a study center

Wang Jianliu
Peking, Beijing 100044
China
Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.